Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate ... ECGs, clinical laboratory tests, physical examinations, and visual analogue mood ...

Effects on clinical parameters including days with lesions ... into Phase 1b studies after each long-acting helicase-primase inhibitor candidate exceeded the company’s target PK profiles in Phase 1a ...

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

Moderna Inc (NASDAQ:MRNA) saw its stock rise 3.8% after announcing that its experimental flu vaccine, mRNA-1010, delivered ...

Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to ...

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress ...

Across dose levels 1 and 2, THE001 + RHT demonstrated a favorable safety profile. There were no dose-limiting toxicities or high-grade treatment-related adverse events that led to treatment ...

Liver and Lipid Profile ... is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders.

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative ...

SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented ...